Literature DB >> 14585516

Drug reimbursement in Finland-a case of explicit prioritizing in special categories.

Lauri Vuorenkoski1, Hanna Toiviainen, Elina Hemminki.   

Abstract

Increased drug expenses have created challenges for drug reimbursement systems in many industrialised countries, including Finland. Prioritization of drugs could be one solution to this problem. This paper examines stakeholders' perspectives on the prioritization decisions made in the Finnish drug reimbursement system, particularly concerning drugs in the higher reimbursement categories. The analysis was based on 18 interviews with key stakeholders. The results revealed that authorities directly influencing the decisions tried to keep them as technical and non-political as possible. However, doing so was not easy, and there appeared to be hidden non-technical rationales behind many decisions. Stakeholders outside public administration had few opportunities to openly participate in decision-making because of the lack of transparency of the process. Despite this, they tried to influence decisions concerning their interests by using several means, such as lobbying the media, Parliament or other stakeholders. Transparent decision-making and better methods of open discussion on competing interests could promote democracy in the prioritization of drugs and perhaps reduce the harmful effects of indirect and unequal participation by different stakeholders.

Mesh:

Substances:

Year:  2003        PMID: 14585516     DOI: 10.1016/s0168-8510(03)00042-3

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  4 in total

1.  Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients.

Authors:  Mireille M Goetghebeur; Monika Wagner; Hanane Khoury; Donna Rindress; Jean-Pierre Grégoire; Cheri Deal
Journal:  Cost Eff Resour Alloc       Date:  2010-04-08

2.  Recent developments in targeting access to high cost medicines in Australia.

Authors:  Christine Y Lu; Jan Ritchie; Kenneth M Williams; Richard O Day
Journal:  Aust New Zealand Health Policy       Date:  2005-11-23

3.  Databases as policy instruments. About extending networks as evidence-based policy.

Authors:  Antoinette de Bont; Herman Stoevelaar; Roland Bal
Journal:  BMC Health Serv Res       Date:  2007-12-07       Impact factor: 2.655

4.  Comorbid diseases as predictors of survival of primary total hip and knee replacements: a nationwide register-based study of 96 754 operations on patients with primary osteoarthritis.

Authors:  Esa Jämsen; Mikko Peltola; Antti Eskelinen; Matti U K Lehto
Journal:  Ann Rheum Dis       Date:  2012-12-19       Impact factor: 19.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.